A. Dexamethasone B. A 5HT₃ receptor antagonist C. An NK₁ receptor antagonist D. All of the above

A. Studies have shown that olanzapine is superior to aprepitant for the treatment of breakthrough nausea/vomiting B. Using an agent with a different mechanism of action, other than what was given for prophylaxis is preferable (e.g., NK₁ or 5HT₃) C. Rolapitant is indicated for the treatment of breakthrough nausea/vomiting at a dose of 90 mg by mouth (PO) daily D. A prescription for breakthrough nausea/vomiting should only be provided to patients with a high likelihood of vomiting after chemotherapy

A. Dexamethasone B. Netupitant-palonosetron C. Palonosetron D. Metoclopramide

A. Histamine B. Serotonin type 2 C. Neurokinin-1 D. Dopamine

A. Complete response rates in the overall period has been shown to be statistically significantly better with an olanzapine prophylaxis regimen compared with an aprepitant regimen B. Rates of delayed emesis has been shown to be statistically significantly better with an olanzapine prophylaxis regimen compared with an aprepitant regimen C. Since olanzapine inhibits serotonin receptors, 5HT₃ receptor antagonists do not have to be administered when using an olanzapine prophylaxis regimen D. An olanzapine prophylaxis regimen may confer better control of nausea compared with an aprepitant regimen and it is dexamethasone-sparing

A. NEPA has been shown to be statistically better than a regimen consisting of aprepitant plus a 5HT₃ receptor antagonist at controlling emesis caused by high emetic risk regimens in the overall period B. The efficacy of NEPA is consistent with the a regimen involving aprepitant plus a 5HT₃ receptor antagonist for the prevention of CINV caused by high emetic risk regimens C. NEPA has been shown to be statistically inferior compared with a regimen consisting of aprepitant plus a 5HT₃ receptor antagonist for controlling emesis caused by high emetic risk regimens in the delayed period D. The efficacy of NEPA is unknown because no clinical trials have compared NEPA with a regimen containing aprepitant

A. Rolapitant is effective for the prevention of delayed emesis in patients receiving highly or moderately emetogenic chemotherapy B. Rolapitant is effective for the prevention of delayed emesis in patients receiving highly emetogenic chemotherapy, but not moderately emetogenic chemotherapy C. Rolapitant is more effective than aprepitant for the prevention of delayed emesis in patients receiving highly emetogenic chemotherapy D. Rolapitant is less effective than aprepitant for the prevention of delayed emesis in patients receiving highly emetogenic chemotherapy

A. The safety and drug interaction profile is identical to other established agents within their respective classes B. Side effects are similar to other established agents within their respective classes, but rolapitant has a different drug interaction profile C. Due to differences in pharmacodynamics, both NEPA and rolapitant have a higher rate of adverse events compared with other established agents within their respective classes D. Due to differences in pharmacokinetics, both NEPA and rolapitant have a lower rate of adverse events compared with other established agents within their respective classes

A. Counseling patients regarding the adverse effects of their antiemetic therapy B. Finding the lowest-cost therapy for patients C. Integrating the guideline recommendations into clinical decision support systems D. Identifying drug interactions between CINV regimens and the patient's ongoing medications

A. There are many prophylaxis regimens available for preventing the CINV caused by high emetic risk regimens B. Using a rescue medication with a different mechanism of action than those used for prophylaxis will tend to improve breakthrough nausea and vomiting control C. Patients now have both oral and intravenous options that are administered or taken before chemotherapy and no longer require repeat dosing on subsequent days D. All of the above are important considerations